DETAILED DESCRIPTION OF THE INVENTION [0015] The invention relates to the pharmaceutical compositions capable of delivering sufficient dose of semaglutide via intranasal routes
Patients should be monitored closely for any signs of respiratory distress
Research published in the New England Journal of Medicine, involving 1,961 overweight obese adults without type 2 diabetes, found that while those given a placebo in addition to lifestyle interventions lost an average of 2.6kg over the course of the 68-week study, those given a weekly injection with semaglutide alongside lifestyle interventions lost 15.3kg on average
Clinical evaluation, not auto-approval You meet with a real provider before anything is prescribed
The Phase 3 trial for obesity and related conditions initiated in 2025
For musculoskeletal injuries, the best evidence supports structured rehabilitation and progressive loading through exercise programs designed by physiotherapy and sports medicine professionals